These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 32798213)

  • 1. Real-world adverse events associated with CAR T-cell therapy among adults age ≥ 65 years.
    Zettler ME; Feinberg BA; Phillips EG; Klink AJ; Mehta S; Gajra A
    J Geriatr Oncol; 2021 Mar; 12(2):239-242. PubMed ID: 32798213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dermatologic Adverse Events Associated With Chimeric Antigen Receptor T-Cell Therapy: A Pharmacovigilance Analysis of the FDA Reporting System.
    Storgard R; Dusza S; Shouval R; Scordo M; Markova A
    Transplant Cell Ther; 2024 Oct; 30(10):1035.e1-1035.e7. PubMed ID: 38945480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Outcomes with Chimeric Antigen Receptor T Cell Therapies in Large B Cell Lymphoma: A Systematic Review and Meta-Analysis.
    Jacobson CA; Munoz J; Sun F; Kanters S; Limbrick-Oldfield EH; Spooner C; Mignone K; Ayuk F; Sanderson R; Whitmore J; Wang Y; Xu H; Dickinson M
    Transplant Cell Ther; 2024 Jan; 30(1):77.e1-77.e15. PubMed ID: 37890589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Axicabtagene Ciloleucel: Clinical Data for the Use of CAR T-cell Therapy in Relapsed and Refractory Large B-cell Lymphoma.
    Halford Z; Anderson MK; Bennett LL
    Ann Pharmacother; 2021 Mar; 55(3):390-405. PubMed ID: 32698673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Model to Estimate Cytokine Release Syndrome and Neurological Event Management Costs Associated With CAR T-Cell Therapy.
    Badaracco J; Gitlin M; Keating SJ
    Transplant Cell Ther; 2023 Jan; 29(1):59.e1-59.e6. PubMed ID: 36272529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparing Efficacy, Safety, and Preinfusion Period of Axicabtagene Ciloleucel versus Tisagenlecleucel in Relapsed/Refractory Large B Cell Lymphoma.
    Oluwole OO; Jansen JP; Lin VW; Chan K; Keeping S; Navale L; Locke FL
    Biol Blood Marrow Transplant; 2020 Sep; 26(9):1581-1588. PubMed ID: 32561336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world healthcare resource utilization and costs associated with tisagenlecleucel and axicabtagene ciloleucel among patients with diffuse large B-cell lymphoma: an analysis of hospital data in the United States.
    Maziarz RT; Yang H; Liu Q; Wang T; Zhao J; Lim S; Lee S; Dalal A; Bollu V
    Leuk Lymphoma; 2022 Sep; 63(9):2052-2062. PubMed ID: 35422192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma.
    Kwon M; Iacoboni G; Reguera JL; Corral LL; Morales RH; Ortiz-Maldonado V; Guerreiro M; Caballero AC; Domínguez MLG; Pina JMS; Mussetti A; Sancho JM; Bastos-Oreiro M; Catala E; Delgado J; Henriquez HL; Sanz J; Calbacho M; Bailén R; Carpio C; Ribera JM; Sureda A; Briones J; Hernandez-Boluda JC; Cebrián NM; Martin JLD; Martín A; Barba P
    Haematologica; 2023 Jan; 108(1):110-121. PubMed ID: 35770532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the United States.
    Liu R; Oluwole OO; Diakite I; Botteman MF; Snider JT; Locke FL
    J Med Econ; 2021; 24(1):458-468. PubMed ID: 33691581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-Marketing Surveillance of CAR-T-Cell Therapies: Analysis of the FDA Adverse Event Reporting System (FAERS) Database.
    Fusaroli M; Isgrò V; Cutroneo PM; Ferrajolo C; Cirillo V; Del Bufalo F; Raschi E; Poluzzi E; Trifirò G
    Drug Saf; 2022 Aug; 45(8):891-908. PubMed ID: 35829913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurological adverse events following CAR T-cell therapy: a real-world analysis.
    Gajra A; Zettler ME; Phillips EG; Klink AJ; Jonathan K Kish ; Fortier S; Mehta S; Feinberg BA
    Immunotherapy; 2020 Oct; 12(14):1077-1082. PubMed ID: 32808566
    [No Abstract]   [Full Text] [Related]  

  • 12. Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma.
    Topp MS; van Meerten T; Houot R; Minnema MC; Bouabdallah K; Lugtenburg PJ; Thieblemont C; Wermke M; Song KW; Avivi I; Kuruvilla J; Dührsen U; Zheng Y; Vardhanabhuti S; Dong J; Bot A; Rossi JM; Plaks V; Sherman M; Kim JJ; Kerber A; Kersten MJ
    Br J Haematol; 2021 Nov; 195(3):388-398. PubMed ID: 34590303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tocilizumab Prophylaxis Following Axicabtagene Ciloleucel in Relapsed or Refractory Large B-Cell Lymphoma.
    Locke FL; Neelapu SS; Bartlett NL; Lekakis LJ; Jacobson CA; Braunschweig I; Oluwole OO; Siddiqi T; Lin Y; Timmerman JM; Kersten MJ; Zheng Y; Zhang T; Nater J; Shen R; Miao H; Kim JJ; Miklos DB
    Transplant Cell Ther; 2024 Nov; 30(11):1065-1079. PubMed ID: 39187161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of axicabtagene ciloleucel versus lisocabtagene maraleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the US.
    Oluwole OO; Liu R; Diakite I; Feng C; Patel A; Nourhussein I; Snider JT; Locke FL
    J Med Econ; 2022; 25(1):541-551. PubMed ID: 35443867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes and factors impacting use of axicabtagene ciloleucel in patients with relapsed or refractory large B-cell lymphoma: results from an intention-to-treat analysis.
    Mian A; Wei W; Winter AM; Khouri J; Jagadeesh D; Anwer F; Gerds AT; Dean RM; Sobecks R; Pohlman B; Hamilton BK; Majhail NS; Hill BT
    Leuk Lymphoma; 2021 Jun; 62(6):1344-1352. PubMed ID: 33375873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase 2 study of axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma in Japan: 1-year follow-up and biomarker analysis.
    Kato K; Fujii N; Makita S; Goto H; Kanda J; Shimada K; Akashi K; Izutsu K; Teshima T; Fukuda N; Sumitani T; Nakamura S; Sumi H; Shimizu S; Kakurai Y; Yoshikawa K; Tobinai K; Usui N; Hatake K
    Int J Hematol; 2023 Mar; 117(3):409-420. PubMed ID: 36399286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Axicabtagene Ciloleucel and Tisagenlecleucel Administration in Lymphoma Patients With Secondary CNS Involvement: A Systematic Review.
    Wu X; Zhang X; Xun R; Liu M; Sun Z; Huang J
    Front Immunol; 2021; 12():693200. PubMed ID: 34290712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A national service for delivering CD19 CAR-Tin large B-cell lymphoma - The UK real-world experience.
    Kuhnl A; Roddie C; Kirkwood AA; Tholouli E; Menne T; Patel A; Besley C; Chaganti S; Sanderson R; O'Reilly M; Norman J; Osborne W; Bloor A; Lugthart S; Malladi R; Patten PEM; Neill L; Martinez-Cibrian N; Kennedy H; Phillips EH; Jones C; Sharplin K; El-Sharkawi D; Latif AL; Mathew A; Uttenthal B; Stewart O; Marzolini MAV; Townsend W; Cwynarski K; Ardeshna K; Ardavan A; Robinson K; Pagliuca A; Collins GP; Johnson R; McMillan A
    Br J Haematol; 2022 Aug; 198(3):492-502. PubMed ID: 35485402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety assessment of anti-B cell maturation antigen chimeric antigen receptor T cell therapy: a real-world study based on the FDA adverse event reporting system database.
    Liu W; Lin S; Zhu X; Yin L; Liu Q; Lei S; Feng B
    Front Immunol; 2024; 15():1433075. PubMed ID: 39290710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Best Treatment Option for Patients With Refractory Aggressive B-Cell Lymphoma in the CAR-T Cell Era: Real-World Evidence From GELTAMO/GETH Spanish Groups.
    Bastos-Oreiro M; Gutierrez A; Reguera JL; Iacoboni G; López-Corral L; Terol MJ; Ortíz-Maldonado V; Sanz J; Guerra-Dominguez L; Bailen R; Mussetti A; Abrisqueta P; Hernani R; Luzardo H; Sancho JM; Delgado-Serrano J; Salar A; Grande C; Bento L; González de Villambrosía S; García-Belmonte D; Sureda A; Pérez-Martínez A; Barba P; Kwon M; Martín García-Sancho A
    Front Immunol; 2022; 13():855730. PubMed ID: 35911769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.